Why are pharmaceutical companies in China using indirect advertising methods—such as metro station banners about snoring or gym partnerships—to promote weight-loss drugs?

Because China prohibits drug companies from directly advertising prescription medicines to consumers; instead, they are allowed to provide public information about disease risks and encourage consultation with doctors—so campaigns avoid mentioning product names but use symptoms (e.g., snoring linked to sleep apnea) or conditions (e.g., fatty liver disease) associated with obesity to indirectly prompt people to seek medical help for weight-related health issues.

Which companies are competing in China’s GLP-1 weight-loss injection market, and how are they timing their market entries?

Novo Nordisk, Eli Lilly, Pfizer, and Innovent Biologics are competing in China’s GLP-1 weight-loss injection market; Novo launched the first once-weekly GLP-1 for weight management in late 2024, Lilly followed in January 2025, Pfizer’s Xianweiying saw its first prescriptions in April 2025, and Innovent launched its mazdutide (Xinermei) in July 2025.

Snoring, Subways and Stealth Ads: How Big Pharma Targets China's Waistline

Aug 23, 2026

Major pharmaceutical companies employ indirect marketing to promote weight-loss drugs in China amidst strict regulations. Analysts project the GLP-1 therapy market could reach $4 billion within five to seven years as competition intensifies between Novo Nordisk and Eli Lilly.

reuters

2026-04-30

Not just GLP-1: Peptide-drug conjugate hits 5 obesity targets

2026-05-06

Eli Lilly Commits Additional $4.5 Billion Across Indiana Manufacturing Sites

2026-07-16

Asia Stocks to Track US Slide on Chipmaker Selloff: Markets Wrap

2026-08-23

Snoring, Subways and Stealth Ads: How Big Pharma Targets China's Waistline

Snoring, Subways and Stealth Ads: How Big Pharma Targets China's Waistline

FAQ